The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Acadia Pharmaceuticals Inc. Securities Litigation (2021)
Apr 22, 2021 | ACADIA Pharmaceuticals Inc. Common Stock NASDAQ: ACAD | Case Status: Filed
Filing Deadline: June 18, 2021
If you purchased a significant amount of shares of ACADIA Pharmaceuticals Inc. Common Stock (NASDAQ: ACAD), you have certain options. Investors should contact us before June 18, 2021.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for ACADIA Pharmaceuticals Inc. Common Stock
First Identified Complaint
Denise Marechal, et al. v. Acadia Pharmaceuticals Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violations of the Federal Securities Laws||April 19th, 2021|
|2||U.S. District Court Civil Docket||April 19th, 2021|